3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Lung Neoplasms
19
Ovarian Neoplasms
15
Carcinoma, Non-Small-Cell Lung
14
Fallopian Tube Neoplasms
13
Colorectal Neoplasms
11
Pancreatic Neoplasms
9
Carcinoma, Hepatocellular
8
Melanoma
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Urinary Bladder Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Mycosis Fungoides
5
Lymphoma, T-Cell, Cutaneous
5
Lymphoma, Large B-Cell, Diffuse
5
Prostatic Neoplasms
4
Neoplasms
4
Neoplasm Metastasis
4
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Sezary Syndrome
3
Sarcoma
3
Rectal Neoplasms
3
Myelodysplastic Syndromes
3
Multiple Myeloma
3
Lymphoma, T-Cell
3
Leukemia, Myeloid, Acute
3
Glioblastoma
3
Colonic Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Renal Cell
3
Interventions
Radiotherapy
9
Doxorubicin
7
pazopanib
5
palbociclib
4
Trabectedin
4
Gemcitabine
4
ribociclib
3
pembrolizumab
3
eribulin
3
Magnetic Resonance Spectroscopy
3
selinexor
2
liposomal doxorubicin
2
avelumab
2
abemaciclib
2
Sunitinib
2
Radiation Dose Hypofractionation
2
Radiation
2
Immunoglobulin G
2
Ifosfamide
2
Docetaxel
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zimberelimab
1
temsirolimus
1
sotigalimab
1
sodium thiosulfate
1
sitravatinib
1
silmitasertib
1
sargramostim
1
romidepsin
1
regorafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Liposarcoma
×
Disulfides
×
Clear all
NCT04668300
2026-04-15
DOSa
M.D. Anderson Cancer Center
Phase 2
Active not recruiting
75 enrolled